Physician profile
Freda Chin
NPI 1982645420
$1,371.00
in general payments reported to CMS, 2019-2025
8 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $129 · 2021: $214 · 2022: $260 · 2023: $285 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477 · Entertainment: $153 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.17 |
| Entertainment | $153.27 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $313.18 | 2021-2025 | Clariti Contact Lens |
| Optos, INC. | $308.57 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Vision Care, INC. | $233.91 | 2019-2021 | |
| Alcon Vision LLC | $218.23 | 2023-2025 | Total30, Precision 1 |
| Genentech USA, INC. | $150.00 | 2023 | Vabysmo |
| Allergan, INC. | $84.00 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.27 | 2020 | |
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freda Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.